비교리스트

 카트 문의
시장보고서
상품코드
1425004

세계 방광암 치료 및 진단 시장 : 진단별, 암 유형별, 국가별, 지역별 - 산업 분석, 시장 규모, 시장 점유율 예측(2023-2030년)

Bladder Cancer Therapeutics and Diagnostics Market, By Diagnostic, By Cancer Type, By Country, and By Region - Industry Analysis, Market Size, Market Share & Forecast from 2023-2030
발행일: | 리서치사: AnalystView Market Insights | 페이지 정보: 영문 289 Pages | 배송안내 : 2-3일 (영업일 기준)

    
    
    




※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

보고서 하이라이트

방광암 치료 및 진단 시장 규모는 2022년 37억 9,420만 달러로 2023년부터 2030년까지 연평균 복합 성장률(CAGR) 5.7%로 확대될 전망입니다.

방광암 치료 및 진단 시장 - 시장 역학

방광질환과 이용가능한 치료법에 대한 인식 증가, 헬스케어 지출 확대, 방광암 부담 증가가 시장 수요를 촉진할 것으로 예측됩니다.

방광암 치료 및 진단 시장은 방광질환 및 이용가능한 치료법에 대한 인지도 향상, 의료 지출 확대, 방광암 부담 증대 등의 요인에 힘입어 급성장을 이루려고 합니다. 예를 들어, 2022년 3월, 세계 방광암 환자 연합은 방광암 계발을 위한 “Don't Go Red” 테마를 선언하고, 경고의 징후와 증상에 대한 인식을 높이고, 장기적인 생존과 생활 품질 향상에 대한 조기 발견의 중요성을 강조했습니다. 게다가 방광암 세계의 유병률은 상승 경향에 있으며, 세계암 관측 통계 2020에 따르면 방광암은 세계에서 발생률이 높은 암 톱 10에 들어 있습니다. 이 보고서에서는 2020년에 세계에서 새롭게 발생하는 방광암의 추정 증례 수는 573,278례, 전립선암의 추정 증례 수는 1,414,259건으로 기재되어 있습니다. 이 세계의 암 이환율의 높이는 시장의 중요한 촉진요인이 되고 있습니다.

방광암 치료 및 진단 시장 - 주요 인사이트력

당사의 리서치 애널리스트가 분석한 바에 의하면, 세계의 방광암 치료 및 진단 시장은 예측 기간(2023-2030년)에 있어서 CAGR 약 5.7%로 연간 성장할 것으로 예측되고 있습니다.

방광암 치료 및 진단 시장은 방광질환 및 이용 가능한 치료법에 대한 인지도 향상, 의료지출 확대, 방광암 부담 증대 등을 배경으로 현저한 속도로 성장할 것으로 예측됩니다.

진단 분야별로, 방광경 검사 분야는 2022년에 가장 큰 시장 점유율을 보여줄 것으로 예측됩니다.

암유형별로는 이행세포 방광암이 2022년의 주요 부문였습니다.

지역별로는 북미가 2022년 주요 수익원

방광암 치료 및 진단 시장 - 세그먼테이션 분석 :

세계의 방광암 치료 및 진단 시장은 진단약, 암 유형별, 지역별로 구분됩니다.

진단에 근거하여, 시장은 4개의 부문으로 분할된다 : 방광경 검사, 방광 초음파 검사, 소변 검사 및 다른 진단. 방광경 검사 분야는 가장 높은 수익을 올리고 있으며 예측 기간 동안에도 주도적 지위를 유지할 것으로 예상됩니다. 방광경 검사는 요도에서 삽입하는 특수한 내시경을 사용하여 방광과 요도 내부를 시각화하는 절차이며, 예측 기간 동안 조사 대상 시장의 지배적 인 부문이 될 것으로 예측됩니다. 이 비용 효율적인 방법은 채용 증가, 방광암 유병률 상승, 주요 시장 기업에 의한 제품 발매가 원동력이 되고 있습니다.

시장은 암 유형별로 세 가지 부문으로 분류됩니다 : 마이그레이션 세포 방광암, 편평 상피 방광암 및 기타 암종입니다. 주로 이행세포 방광암의 이환율이 높기 때문에 이행세포 방광암부문은 2030년까지 세계의 방광암 진단약 시장에서 큰 점유율을 차지할 것으로 예측되고 있습니다.

방광암 치료 및 진단 시장 - 지리적 통찰

지리적으로, 이 시장은 북미, 라틴아메리카, 유럽, 아시아태평양, 중동 및 아프리카의 각 지역으로 퍼져 있습니다. 이 지역은 비즈니스를 전개하는 국가에 따라 더 나뉩니다. 북미는 암 유병률 상승으로 예측 기간 동안 시장을 독점할 것으로 예상됩니다. 예를 들어, 미국 암 협회의 2022년 1월의 추계에 따르면, 미국에서는 2022년에 약 81,180례의 방광암이 새롭게 발생해, 그 내역은 남성 61,700례, 여성 19,480례입니다.

방광암 치료 및 진단 시장 - 경쟁 구도 -

방광암 치료 및 진단의 영역에서는 각사가 혁신적인 어프로치의 연구 개발에 열심히 임하고 있습니다. 치료제에서는 방광암의 치료성적을 향상시키기 위한 표적요법, 특히 면역요법의 진전이 주목받고 있습니다. 펨브롤리주맙이나 아테졸리주맙과 같은 약물로 대표되는 면역 체크포인트 억제제는 특정 방광암 유형에 대한 승인을 받았으며, 현재 진행 중인 조사에 의해 치료 옵션의 레퍼토리가 확산되고 있습니다. 또한 각 회사는 조기 발견, 예후, 치료 효과 판정에 도움이 되는 신규 바이오마커의 탐색에 힘을 쏟고 있습니다. 이러한 바이오마커는 진단 방법의 개선과 보다 맞춤 치료 개입의 지침이 되어 환자의 결과를 개선하고 방광암의 전반적인 부담을 줄일 수 있습니다. 이 분야의 기업은 조기 진단부터 혁신적인 치료법에 이르기까지 방광암과 관련된 과제에 종합적으로 임해 환자의 케어와 생존율의 향상을 최종 목표로 하고 있습니다.

목차

제1장 방광암 치료 및 진단 시장 개요

  • 조사 범위
  • 시장 추정 연도

제2장 주요 요약

  • 시장 분석
  • 경쟁 인사이트

제3장 방광암 치료 및 진단의 주요 시장 동향

  • 시장 성장 촉진요인
  • 시장 성장 억제요인
  • 시장 기회
  • 향후 시장 동향

제4장 방광암 치료 및 진단 업계의 조사

  • PEST 분석
  • Porter's Five Forces 분석
  • 성장 전망 맵핑
  • 규제 틀의 분석

제5장 방광암 치료 및 진단 시장 : COVID-19의 영향 분석

  • 신형 코로나 바이러스 유행 전 영향 분석
  • 신형 코로나 바이러스 유행 후 영향 분석

제6장 방광암 치료 및 진단 시장 상황

  • 방광암 치료 및 진단 시장 점유율 분석, 2022년
  • 주요 제조업체별 분석 데이터
    • 기존 기업의 분석
    • 신흥기업의 분석

제7장 방광암 치료 및 진단 시장 - 진단별

  • 개요
    • 진단별 부문 점유율 분석
    • 방광경 검사
    • 방광 초음파 검사
    • 소변 검사
    • 기타 진단

제8장 방광암 치료 및 진단 시장 - 암 유형별

  • 개요
    • 암 유형별 부문 점유율 분석
    • 이행 상피성 방광암
    • 방광 편평상피암
    • 기타 암 유형

제9장 방광암 치료 및 진단 시장 - 지역별

  • 소개
  • 북미
    • 개요
    • 북미의 주요 제조업체
    • 미국
    • 캐나다
  • 유럽
    • 개요
    • 유럽의 주요 제조업체
    • 독일
    • 이탈리아
    • 영국
    • 프랑스
    • 러시아
    • 네덜란드
    • 스웨덴
    • 폴란드
    • 기타
  • 아시아태평양(APAC)
    • 개요
    • 아시아태평양의 주요 제조업체
    • 인도
    • 중국
    • 일본
    • 한국
    • 호주
    • 태국
    • 인도네시아
    • 필리핀
    • 기타
  • 라틴아메리카
    • 개요
    • 라틴아메리카의 주요 제조업체
    • 브라질
    • 멕시코
    • 아르헨티나
    • 콜롬비아
    • 기타
  • 중동 및 아프리카
    • 개요
    • 중동 및 아프리카의 주요 제조업체
    • 사우디아라비아
    • 아랍에미리트(UAE)
    • 이스라엘
    • 터키
    • 알제리
    • 이집트
    • 기타

제10장 주요 벤더 분석 - 방광암 치료 및 진단 업계

  • 경쟁 대시보드
  • 기업 프로파일
    • AstraZeneca
    • Bristol-Myers Squibb Company
    • Lilly
    • F. Hoffmann-La Roche Ltd
    • GSK plc
    • Novartis AG
    • Pfizer Inc.
    • Sanofi
    • Endo Pharmaceuticals Inc.
    • Johnson &Johnson Services

제11장 애널리스트의 전방위 전망

JHS 24.02.28

REPORT HIGHLIGHT

Bladder Cancer Therapeutics and Diagnostics Market size was valued at USD 3,794.2 Million in 2022, expanding at a CAGR of 5.7% from 2023 to 2030.

Acute lymphocytic/lymphoblastic leukemia is a cancer type originating from immature lymphocytes. The term "acute" denotes its rapid progression and spread throughout the body, originating in the bone marrow and swiftly infiltrating other vital organs like the liver, spleen, lymph nodes, central nervous system, and bloodstream. Symptoms may include fatigue, pallor, easy bruising, gum and nosebleeds, weight loss, shortness of breath, and loss of appetite. Multiple therapeutic approaches, including chemotherapy, are utilized in ALL treatment.

Bladder Cancer Therapeutics and Diagnostics Market- Market Dynamics

Increasing awareness of bladder diseases and available therapies, expanding healthcare expenditure, and the mounting burden of bladder cancer is expected to propel the market demand

The bladder cancer therapeutics and diagnostics market is poised for rapid growth, fueled by factors such as increasing awareness of bladder diseases and available therapies, expanding healthcare expenditure, and the mounting burden of bladder cancer. In March 2022, for example, the World Bladder Cancer Patient Coalition declared the 'Don't Go Red' theme for Bladder Cancer Awareness to raise awareness of warning signs and symptoms, underscoring the importance of early detection in enhancing long-term survival and quality of life. Furthermore, the global prevalence of bladder cancer is on the rise, with bladder cancer ranking among the top 10 high-incidence cancers worldwide according to the Global Cancer Observatory Statistics 2020. In the same report, it was noted that in 2020, there were an estimated 573,278 new cases of bladder cancer and 1,414,259 cases of prostate cancer worldwide. This high incidence of cancer globally is a significant driver for the market.

Bladder Cancer Therapeutics and Diagnostics Market- Key Insights

As per the analysis shared by our research analyst, the global Bladder Cancer Therapeutics and Diagnostics Market is estimated to grow annually at a CAGR of around 5.7% over the forecast period (2023-2030)

The Bladder Cancer Therapeutics and Diagnostics Market is projected to grow at a significant rate driven by increasing awareness of bladder diseases and available therapies, expanding healthcare expenditure, and the mounting burden of bladder cancer

Based on Diagnostic, the Cystoscopy segment was predicted to show maximum market share in the year 2022

Based on Cancer Type, Transitional Cell Bladder Cancer was the leading Segment in 2022

On the basis of region, North America was the leading revenue generator in 2022

Bladder Cancer Therapeutics and Diagnostics Market- Segmentation Analysis:

The Global Bladder Cancer Therapeutics and Diagnostics Market is segmented on the basis of Diagnostic, By Cancer Type, and Region.

Based on the Diagnostic, the market is divided into four segments: Cystoscopy, Bladder Ultrasound, Urinalysis, Other Diagnostics. The Cystoscopy segment generated the highest revenue, and it is expected to maintain its leading position throughout the forecast period. Cystoscopy, a procedure for visualizing the interior of the bladder and urethra using a specialized endoscope inserted through the urethra, is projected to be the dominant segment in the studied market during the forecast period. This cost-effective method is driven by increasing adoption, the rising prevalence of bladder cancer, and product launches by key market players.

The market is categorized by Cancer Type into three segments: Transitional Cell Bladder Cancer, Squamous Cell Bladder Cancer, Other Cancer Types. The transitional cell bladder cancer segment is expected to hold a significant share of the global bladder cancer diagnostics market by 2030, primarily due to the high incidence of transitional cell bladder cancer.

Bladder Cancer Therapeutics and Diagnostics Market- Geographical Insights

Geographically, this market is widespread into the regions of North America, Latin America, Europe, Asia Pacific, and the Middle East and Africa. These regions are further divided as per the nations bringing business. North America is expected to dominate the market during the forecast period owing to the rising prevalence of cancer. For instance, as to the January 2022 estimates from the American Cancer Society, about 81,180 new cases of bladder cancer would occur in the United States year 2022, with 61,700 cases in men and 19,480 cases in women.

Bladder Cancer Therapeutics and Diagnostics Market- Competitive Landscape:

In the realm of bladder cancer therapeutics and diagnostics, companies are fervently researching and developing innovative approaches. In therapeutics, a notable focus is on the advancement of targeted therapies, particularly immunotherapies, to enhance bladder cancer treatment outcomes. Immune checkpoint inhibitors, exemplified by drugs like pembrolizumab and atezolizumab, have secured approvals for specific bladder cancer types, and ongoing investigations are expanding the repertoire of treatment options. Moreover, companies are dedicated to exploring novel biomarkers that can aid in early detection, prognosis, and treatment response assessment. These biomarkers can help refine diagnostic methods and guide more personalized therapeutic interventions, potentially improving patient outcomes and reducing the overall burden of bladder cancer. Companies in this space are committed to addressing the challenges associated with bladder cancer comprehensively, from early diagnosis to innovative treatment modalities, with the ultimate goal of enhancing patient care and survival rates.

Recent Developments:

In July 2022, the United States Food and Cancer Type Administration (FDA) agreed to review ImmunityBio's Biologics License Diagnostic (BLA) for N-803, which could benefit patients with or without Ta or T1 illness who have non-muscle-invasive bladder cancer (NMIBC) carcinoma in situ (CIS).

SCOPE OF THE REPORT

The scope of this report covers the market by its major segments, which include as follows:

GLOBAL BLADDER CANCER THERAPEUTICS AND DIAGNOSTICS MARKET KEY PLAYERS

  • AstraZeneca
  • Bristol-Myers Squibb Company
  • Lilly
  • F. Hoffmann-La Roche Ltd
  • GSK plc
  • Novartis AG
  • Pfizer Inc.
  • Sanofi
  • Endo Pharmaceuticals Inc.
  • Johnson & Johnson Services

GLOBAL BLADDER CANCER THERAPEUTICS AND DIAGNOSTICS MARKET, BY DIAGNOSTIC

  • Cystoscopy
  • Bladder Ultrasound
  • Urinalysis
  • Other Diagnostics

GLOBAL BLADDER CANCER THERAPEUTICS AND DIAGNOSTICS MARKET, BY CANCER TYPE

  • Transitional Cell Bladder Cancer
  • Squamous Cell Bladder Cancer
  • Other Cancer Types

GLOBAL BLADDER CANCER THERAPEUTICS AND DIAGNOSTICS MARKET, BY REGION

  • North America
  • The U.S.
  • Canada
  • Europe
  • Germany
  • France
  • Italy
  • Spain
  • United Kingdom
  • Russia
  • Netherlands
  • Sweden
  • Poland
  • Rest of Europe
  • Asia Pacific
  • India
  • China
  • South Korea
  • Japan
  • Australia
  • Thailand
  • Indonesia
  • Philippines
  • Rest of APAC
  • Latin America
  • Brazil
  • Mexico
  • Argentina
  • Colombia
  • Rest of LATAM
  • The Middle East and Africa
  • Saudi Arabia
  • United Arab Emirates
  • Israel
  • Turkey
  • Algeria
  • Egypt
  • Rest of MEA

Table of Contents

1. Bladder Cancer Therapeutics and Diagnostics Market Overview

  • 1.1. Study Scope
  • 1.2. Market Estimation Years

2. Executive Summary

  • 2.1. Market Snippet
    • 2.1.1. Bladder Cancer Therapeutics and Diagnostics Market Snippet by Diagnostics
    • 2.1.2. Bladder Cancer Therapeutics and Diagnostics Market Snippet by Cancer Type
    • 2.1.3. Bladder Cancer Therapeutics and Diagnostics Market Snippet by Country
    • 2.1.4. Bladder Cancer Therapeutics and Diagnostics Market Snippet by Region
  • 2.2. Competitive Insights

3. Bladder Cancer Therapeutics and Diagnostics Key Market Trends

  • 3.1. Bladder Cancer Therapeutics and Diagnostics Market Drivers
    • 3.1.1. Impact Analysis of Market Drivers
  • 3.2. Bladder Cancer Therapeutics and Diagnostics Market Restraints
    • 3.2.1. Impact Analysis of Market Restraints
  • 3.3. Bladder Cancer Therapeutics and Diagnostics Market Opportunities
  • 3.4. Bladder Cancer Therapeutics and Diagnostics Market Future Trends

4. Bladder Cancer Therapeutics and Diagnostics Industry Study

  • 4.1. PEST Analysis
  • 4.2. Porter's Five Forces Analysis
  • 4.3. Growth Prospect Mapping
  • 4.4. Regulatory Framework Analysis

5. Bladder Cancer Therapeutics and Diagnostics Market: COVID-19 Impact Analysis

  • 5.1. Pre-COVID-19 Impact Analysis
  • 5.2. Post-COVID-19 Impact Analysis
    • 5.2.1. Top Performing Segments
    • 5.2.2. Marginal Growth Segments
    • 5.2.3. Top Looser Segments
    • 5.2.4. Marginal Loss Segments

6. Bladder Cancer Therapeutics and Diagnostics Market Landscape

  • 6.1. Bladder Cancer Therapeutics and Diagnostics Market Share Analysis, 2022
  • 6.2. Breakdown Data, by Key Manufacturer
    • 6.2.1. Established Players' Analysis
    • 6.2.2. Emerging Players' Analysis

7. Bladder Cancer Therapeutics and Diagnostics Market - By Diagnostics

  • 7.1. Overview
    • 7.1.1. Segment Share Analysis, By Diagnostics, 2022 & 2030 (%)
    • 7.1.2. Cystoscopy
    • 7.1.3. Bladder Ultrasound
    • 7.1.4. Urinalysis
    • 7.1.5. Other Diagnostics

8. Bladder Cancer Therapeutics and Diagnostics Market - By Cancer Type

  • 8.1. Overview
    • 8.1.1. Segment Share Analysis, By Cancer Type, 2022 & 2030 (%)
    • 8.1.2. Transitional Cell Bladder Cancer
    • 8.1.3. Squamous Cell Bladder Cancer
    • 8.1.4. Other Cancer Types

9. Bladder Cancer Therapeutics and Diagnostics Market- By Geography

  • 9.1. Introduction
    • 9.1.1. Segment Share Analysis, By Geography, 2022 & 2030 (%)
  • 9.2. North America
    • 9.2.1. Overview
    • 9.2.2. Bladder Cancer Therapeutics and Diagnostics Key Manufacturers in North America
    • 9.2.3. North America Market Size and Forecast, By Country, 2018 - 2030 (US$ Million)
    • 9.2.4. North America Market Size and Forecast, By Diagnostics, 2018 - 2030 (US$ Million)
    • 9.2.5. North America Market Size and Forecast, By Cancer Type, 2018 - 2030 (US$ Million)
    • 9.2.6. U.S.
      • 9.2.6.1. Overview
      • 9.2.6.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 9.2.6.3. U.S. Market Size and Forecast, By Diagnostics, 2018 - 2030 (US$ Million)
      • 9.2.6.4. U.S. Market Size and Forecast, By Cancer Type, 2018 - 2030 (US$ Million)
    • 9.2.7. Canada
      • 9.2.7.1. Overview
      • 9.2.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 9.2.7.3. Canada Market Size and Forecast, By Diagnostics, 2018 - 2030 (US$ Million)
      • 9.2.7.4. Canada Market Size and Forecast, By Cancer Type, 2018 - 2030 (US$ Million)
  • 9.3. Europe
    • 9.3.1. Overview
    • 9.3.2. Bladder Cancer Therapeutics and Diagnostics Key Manufacturers in Europe
    • 9.3.3. Europe Market Size and Forecast, By Country, 2018 - 2030 (US$ Million)
    • 9.3.4. Europe Market Size and Forecast, By Diagnostics, 2018 - 2030 (US$ Million)
    • 9.3.5. Europe Market Size and Forecast, By Cancer Type, 2018 - 2030 (US$ Million)
    • 9.3.6. Germany
      • 9.3.6.1. Overview
      • 9.3.6.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 9.3.6.3. Germany Market Size and Forecast, By Diagnostics, 2018 - 2030 (US$ Million)
      • 9.3.6.4. Germany Market Size and Forecast, By Cancer Type, 2018 - 2030 (US$ Million)
    • 9.3.7. Italy
      • 9.3.7.1. Overview
      • 9.3.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 9.3.7.3. Italy Market Size and Forecast, By Diagnostics, 2018 - 2030 (US$ Million)
      • 9.3.7.4. Italy Market Size and Forecast, By Cancer Type, 2018 - 2030 (US$ Million)
    • 9.3.8. United Kingdom
      • 9.3.8.1. Overview
      • 9.3.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 9.3.8.3. United Kingdom Market Size and Forecast, By Diagnostics, 2018 - 2030 (US$ Million)
      • 9.3.8.4. United Kingdom Market Size and Forecast, By Cancer Type, 2018 - 2030 (US$ Million)
    • 9.3.9. France
      • 9.3.9.1. Overview
      • 9.3.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 9.3.9.3. France Market Size and Forecast, By Diagnostics, 2018 - 2030 (US$ Million)
      • 9.3.9.4. France Market Size and Forecast, By Cancer Type, 2018 - 2030 (US$ Million)
    • 9.3.10. Russia
      • 9.3.10.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 9.3.10.2. Russia Market Size and Forecast, By Diagnostics, 2018 - 2030 (US$ Million)
      • 9.3.10.3. Russia Market Size and Forecast, By Cancer Type, 2018 - 2030 (US$ Million)
    • 9.3.11. Netherlands
      • 9.3.11.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 9.3.11.2. Netherlands Market Size and Forecast, By Diagnostics, 2018 - 2030 (US$ Million)
      • 9.3.11.3. Netherlands Market Size and Forecast, By Cancer Type, 2018 - 2030 (US$ Million)
    • 9.3.12. Sweden
      • 9.3.12.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 9.3.12.2. Sweden Market Size and Forecast, By Diagnostics, 2018 - 2030 (US$ Million)
      • 9.3.12.3. Sweden Market Size and Forecast, By Cancer Type, 2018 - 2030 (US$ Million)
    • 9.3.13. Poland
      • 9.3.13.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 9.3.13.2. Poland Market Size and Forecast, By Diagnostics, 2018 - 2030 (US$ Million)
      • 9.3.13.3. Poland Market Size and Forecast, By Cancer Type, 2018 - 2030 (US$ Million)
    • 9.3.14. Rest of Europe
      • 9.3.14.1. Overview
      • 9.3.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 9.3.14.3. Rest of the Europe Market Size and Forecast, By Diagnostics, 2018 - 2030 (US$ Million)
      • 9.3.14.4. Rest of the Europe Market Size and Forecast, By Cancer Type, 2018 - 2030 (US$ Million)
  • 9.4. Asia Pacific (APAC)
    • 9.4.1. Overview
    • 9.4.2. Bladder Cancer Therapeutics and Diagnostics Key Manufacturers in Asia Pacific
    • 9.4.3. Asia Pacific Market Size and Forecast, By Country, 2018 - 2030 (US$ Million)
    • 9.4.4. Asia Pacific Market Size and Forecast, By Diagnostics, 2018 - 2030 (US$ Million)
    • 9.4.5. Asia Pacific Market Size and Forecast, By Cancer Type, 2018 - 2030 (US$ Million)
    • 9.4.6. India
      • 9.4.6.1. Overview
      • 9.4.6.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 9.4.6.3. India Market Size and Forecast, By Diagnostics, 2018 - 2030 (US$ Million)
      • 9.4.6.4. India Market Size and Forecast, By Cancer Type, 2018 - 2030 (US$ Million)
    • 9.4.7. China
      • 9.4.7.1. Overview
      • 9.4.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 9.4.7.3. China Market Size and Forecast, By Diagnostics, 2018 - 2030 (US$ Million)
      • 9.4.7.4. China Market Size and Forecast, By Cancer Type, 2018 - 2030 (US$ Million)
    • 9.4.8. Japan
      • 9.4.8.1. Overview
      • 9.4.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 9.4.8.3. Japan Market Size and Forecast, By Diagnostics, 2018 - 2030 (US$ Million)
      • 9.4.8.4. Japan Market Size and Forecast, By Cancer Type, 2018 - 2030 (US$ Million)
    • 9.4.9. South Korea
      • 9.4.9.1. Overview
      • 9.4.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 9.4.9.3. South Korea Market Size and Forecast, By Diagnostics, 2018 - 2030 (US$ Million)
      • 9.4.9.4. South Korea Market Size and Forecast, By Cancer Type, 2018 - 2030 (US$ Million)
    • 9.4.10. Australia
      • 9.4.10.1. Overview
      • 9.4.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 9.4.10.3. Australia Market Size and Forecast, By Diagnostics, 2018 - 2030 (US$ Million)
      • 9.4.10.4. Australia Market Size and Forecast, By Cancer Type, 2018 - 2030 (US$ Million)
    • 9.4.11. Thailand
      • 9.4.11.1. Overview
      • 9.4.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 9.4.11.3. Thailand Market Size and Forecast, By Diagnostics, 2018 - 2030 (US$ Million)
      • 9.4.11.4. Thailand Market Size and Forecast, By Cancer Type, 2018 - 2030 (US$ Million)
    • 9.4.12. Indonesia
      • 9.4.12.1. Overview
      • 9.4.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 9.4.12.3. Indonesia Market Size and Forecast, By Diagnostics, 2018 - 2030 (US$ Million)
      • 9.4.12.4. Indonesia Market Size and Forecast, By Cancer Type, 2018 - 2030 (US$ Million)
    • 9.4.13. Philippines
      • 9.4.13.1. Overview
      • 9.4.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 9.4.13.3. Philippines Market Size and Forecast, By Diagnostics, 2018 - 2030 (US$ Million)
      • 9.4.13.4. Philippines Market Size and Forecast, By Cancer Type, 2018 - 2030 (US$ Million)
    • 9.4.14. Rest of APAC
      • 9.4.14.1. Overview
      • 9.4.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 9.4.14.3. Rest of APAC Market Size and Forecast, By Diagnostics, 2018 - 2030 (US$ Million)
      • 9.4.14.4. Rest of APAC Market Size and Forecast, By Cancer Type, 2018 - 2030 (US$ Million)
  • 9.5. Latin America
    • 9.5.1. Overview
    • 9.5.2. Bladder Cancer Therapeutics and Diagnostics Key Manufacturers in Latin America
    • 9.5.3. Latin America Market Size and Forecast, By Country, 2018 - 2030 (US$ Million)
    • 9.5.4. Latin America Market Size and Forecast, By Diagnostics, 2018 - 2030 (US$ Million)
    • 9.5.5. Latin America Market Size and Forecast, By Cancer Type, 2018 - 2030 (US$ Million)
    • 9.5.6. Brazil
      • 9.5.6.1. Overview
      • 9.5.6.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 9.5.6.3. Brazil Market Size and Forecast, By Diagnostics, 2018 - 2030 (US$ Million)
      • 9.5.6.4. Brazil Market Size and Forecast, By Cancer Type, 2018 - 2030 (US$ Million)
    • 9.5.7. Mexico
      • 9.5.7.1. Overview
      • 9.5.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 9.5.7.3. Mexico Market Size and Forecast, By Diagnostics, 2018 - 2030 (US$ Million)
      • 9.5.7.4. Mexico Market Size and Forecast, By Cancer Type, 2018 - 2030 (US$ Million)
    • 9.5.8. Argentina
      • 9.5.8.1. Overview
      • 9.5.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 9.5.8.3. Argentina Market Size and Forecast, By Diagnostics, 2018 - 2030 (US$ Million)
      • 9.5.8.4. Argentina Market Size and Forecast, By Cancer Type, 2018 - 2030 (US$ Million)
    • 9.5.9. Colombia
      • 9.5.9.1. Overview
      • 9.5.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 9.5.9.3. Colombia Market Size and Forecast, By Diagnostics, 2018 - 2030 (US$ Million)
      • 9.5.9.4. Colombia Market Size and Forecast, By Cancer Type, 2018 - 2030 (US$ Million)
    • 9.5.10. Rest of LATAM
      • 9.5.10.1. Overview
      • 9.5.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 9.5.10.3. Rest of LATAM Market Size and Forecast, By Diagnostics, 2018 - 2030 (US$ Million)
      • 9.5.10.4. Rest of LATAM Market Size and Forecast, By Cancer Type, 2018 - 2030 (US$ Million)
  • 9.6. Middle East and Africa
    • 9.6.1. Overview
    • 9.6.2. Bladder Cancer Therapeutics and Diagnostics Key Manufacturers in Middle East and Africa
    • 9.6.3. Middle East and Africa Market Size and Forecast, By Country, 2018 - 2030 (US$ Million)
    • 9.6.4. Middle East and Africa Market Size and Forecast, By Diagnostics, 2018 - 2030 (US$ Million)
    • 9.6.5. Middle East and Africa Market Size and Forecast, By Cancer Type, 2018 - 2030 (US$ Million)
    • 9.6.6. Saudi Arabia
      • 9.6.6.1. Overview
      • 9.6.6.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 9.6.6.3. Saudi Arabia Market Size and Forecast, By Diagnostics, 2018 - 2030 (US$ Million)
      • 9.6.6.4. Saudi Arabia Market Size and Forecast, By Cancer Type, 2018 - 2030 (US$ Million)
    • 9.6.7. United Arab Emirates
      • 9.6.7.1. Overview
      • 9.6.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 9.6.7.3. United Arab Emirates Market Size and Forecast, By Diagnostics, 2018 - 2030 (US$ Million)
      • 9.6.7.4. United Arab Emirates Market Size and Forecast, By Cancer Type, 2018 - 2030 (US$ Million)
    • 9.6.8. Israel
      • 9.6.8.1. Overview
      • 9.6.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 9.6.8.3. Israel Market Size and Forecast, By Diagnostics, 2018 - 2030 (US$ Million)
      • 9.6.8.4. Israel Market Size and Forecast, By Cancer Type, 2018 - 2030 (US$ Million)
    • 9.6.9. Turkey
      • 9.6.9.1. Overview
      • 9.6.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 9.6.9.3. Turkey Market Size and Forecast, By Diagnostics, 2018 - 2030 (US$ Million)
      • 9.6.9.4. Turkey Market Size and Forecast, By Cancer Type, 2018 - 2030 (US$ Million)
    • 9.6.10. Algeria
      • 9.6.10.1. Overview
      • 9.6.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 9.6.10.3. Algeria Market Size and Forecast, By Diagnostics, 2018 - 2030 (US$ Million)
      • 9.6.10.4. Algeria Market Size and Forecast, By Cancer Type, 2018 - 2030 (US$ Million)
    • 9.6.11. Egypt
      • 9.6.11.1. Overview
      • 9.6.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 9.6.11.3. Egypt Market Size and Forecast, By Diagnostics, 2018 - 2030 (US$ Million)
      • 9.6.11.4. Egypt Market Size and Forecast, By Cancer Type, 2018 - 2030 (US$ Million)
    • 9.6.12. Rest of MEA
      • 9.6.12.1. Overview
      • 9.6.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 9.6.12.3. Rest of MEA Market Size and Forecast, By Diagnostics, 2018 - 2030 (US$ Million)
      • 9.6.12.4. Rest of MEA Market Size and Forecast, By Cancer Type, 2018 - 2030 (US$ Million)

10. Key Vendor Analysis- Bladder Cancer Therapeutics and Diagnostics Industry

  • 10.1. Competitive Dashboard
  • 10.2. Company Profiles
    • 10.2.1. AstraZeneca
    • 10.2.2. Bristol-Myers Squibb Company
    • 10.2.3. Lilly
    • 10.2.4. F. Hoffmann-La Roche Ltd
    • 10.2.5. GSK plc
    • 10.2.6. Novartis AG
    • 10.2.7. Pfizer Inc.
    • 10.2.8. Sanofi
    • 10.2.9. Endo Pharmaceuticals Inc.
    • 10.2.10. Johnson & Johnson Services

11. 360 Degree Analyst View

12. Appendix

  • 12.1. Research Methodology
  • 12.2. References
  • 12.3. Abbreviations
  • 12.4. Disclaimer
  • 12.5. Contact Us
비교리스트
0 건의 상품을 선택 중
상품 비교하기
전체삭제